BRCA1 haplotype and clinical benefit of trabectedin in soft-tissue sarcoma patients

Long-term outcome and effect of maintenance therapy in patients with advanced sarcoma treated with trabectedin: an analysis of 181 patients of the French ATU compassionate use program

(2013) Jean-Yves Blay et al.   BMC CANCER

ERCC5/XPG, ERCC1, and BRCA1 gene status and clinical benefit of trabectedin in patients with soft tissue sarcoma

(2011) Antoine Italiano et al.   CANCER

Predictive impact of DNA repair functionality on clinical outcome of advanced sarcoma patients treated with trabectedin: A retrospective multicentric study

(2011) P. Schöffski et al.   EUROPEAN JOURNAL OF CANCER

BRCA Gene Structure and Function in Tumor Suppression

(2010) Conleth G. Murphy et al.   CANCER JOURNAL

BRCA1 and XRCC1 polymorphisms associated with survival in advanced gastric cancer treated with taxane and cisplatin

(2010) Hyun Jeong Shim et al.   CANCER SCIENCE

Validated prediction of clinical outcome in sarcomas and multiple types of cancer on the basis of a gene expression signature related to genome complexity

(2010) Frédéric Chibon et al.   NATURE MEDICINE

Efficacy and Safety of Trabectedin in Patients With Advanced or Metastatic Liposarcoma or Leiomyosarcoma After Failure of Prior Anthracyclines and Ifosfamide: Results of a Randomized Phase II Study of Two Different Schedules

(2009) George D. Demetri et al.   JOURNAL OF CLINICAL ONCOLOGY

BRCA1 and its toolbox for the maintenance of genome integrity

(2009) Michael S.Y. Huen et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Effect ofBRCA1Haplotype on Survival of Non–Small-Cell Lung Cancer Patients Treated With Platinum-Based Chemotherapy

(2008) Hong-Tae Kim et al.   JOURNAL OF CLINICAL ONCOLOGY